Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026
Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Fineline Cube Jul 1, 2026
Company Deals Hospital Medical Device

Siemens Healthineers Collaborates with MGH to Advance Theranostics Applications

Fineline Cube Jun 25, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant, has entered into a research...

Company Drug

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

Fineline Cube Jun 25, 2025

The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...

Company Drug

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

Fineline Cube Jun 25, 2025

China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...

Company Deals Drug

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Fineline Cube Jun 25, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...

Company Drug

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Fineline Cube Jun 25, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...

Company Drug

Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit

Fineline Cube Jun 24, 2025

China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...

Company Medical Device

Broncus Medical Wins NMPA Approval for BroncAblate RFA System Console

Fineline Cube Jun 24, 2025

Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216)...

Policy / Regulatory

NHSA Implements Region-Based Pricing System for Medical Services

Fineline Cube Jun 24, 2025

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Optimizing Medical Service...

Company Deals

Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East

Fineline Cube Jun 24, 2025

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...

Company Deals

Bio-Thera Partners with SteinCares for Biosimilar Commercialization in Latin America

Fineline Cube Jun 24, 2025

Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing...

Company Drug

Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment

Fineline Cube Jun 24, 2025

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial...

Company Drug R&D

Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks

Fineline Cube Jun 24, 2025

Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease...

Company Drug

Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial

Fineline Cube Jun 24, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...

Company Drug

GSK’s Linerixibat Accepted for EMA Review for Cholestatic Pruritus in PBC

Fineline Cube Jun 24, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted the...

Company Drug

Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma

Fineline Cube Jun 24, 2025

France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...

Policy / Regulatory

Beijing Tightens Price Risk Management for Scarce Medications

Fineline Cube Jun 24, 2025

The Beijing Municipal Medical Insurance Bureau issued the “Notice on Further Strengthening Price Risk Management...

Company Deals

Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development

Fineline Cube Jun 24, 2025

Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...

Company Deals

Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study

Fineline Cube Jun 24, 2025

US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...

Company Drug

Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease

Fineline Cube Jun 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...

Company Deals

Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration

Fineline Cube Jun 24, 2025

US major Illumina (NASDAQ: ILMN) announced plans to acquire SomaLogic, a leader in data-driven proteomics...

Posts pagination

1 … 161 162 163 … 689

Recent updates

  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
  • Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.